Literature DB >> 10906907

Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

L P Boulet1, A Becker, D Bérubé, R Beveridge, P Ernst.   

Abstract

OBJECTIVES: To provide physicians with current guidelines for the diagnosis and optimal management of asthma in children and adults, including pregnant women and the elderly, in office, emergency department, hospital and clinic settings. OPTIONS: The consensus group considered the roles of education, avoidance of provocative environmental and other factors, diverse pharmacotherapies, delivery devices and emergency and in-hospital management of asthma. OUTCOMES: Provision of the best control of asthma by confirmation of the diagnosis using objective measures, rapid achievement and maintenance of control and regular follow-up. EVIDENCE: The key diagnostic and therapeutic recommendations are based on the 1995 Canadian guidelines and a critical review of the literature by small groups before a full meeting of the consensus group. Recommendations are graded according to 5 levels of evidence. Differences of opinion were resolved by consensus following discussion. VALUES: Respirologists, immunoallergists, pediatricians and emergency and family physicians gave prime consideration to the achievement and maintenance of optimal control of asthma through avoidance of environmental inciters, education of patients and the lowest effective regime of pharmacotherapy to reduce morbidity and mortality. BENEFITS, HARMS AND COSTS: Adherence to the guidelines should be accompanied by significant reduction in patients' symptoms, reduced morbidity and mortality, fewer emergency and hospital admissions, fewer adverse side-effects from medications, better quality of life for patients and reduced costs. RECOMMENDATIONS: Recommendations are included in each section of the report. In summary, after a diagnosis of asthma is made based on clinical evaluation, including demonstration of variable airflow obstruction, and contributing factors are identified, a treatment plan is established to obtain and maintain optimal asthma control. The main components of treatment are patient education, environmental control, pharmacotherapy tailored to the individual and regular follow-up. VALIDATION: The recommendations were distributed to the members of the Canadian Thoracic Society Asthma and Standards Committees, as well as members of the board of the Canadian Thoracic Society. In addition, collaborating groups representing the Canadian Association of Emergency Physicians, the Canadian College of Family Physicians, the Canadian Paediatric Society and the Canadian Society of Allergy and Immunology were asked to validate the recommendations. The recommendations were discussed at regional meetings throughout Canada. They were also compared with the recommendations of other similar groups in other countries. DISSEMINATION AND IMPLEMENTATION: An implementation committee has established a strategy for disseminating these guidelines to physicians, other health professionals and patients and for developing tools and means that will help integrate the recommendations into current asthma care. The plan is outlined in this report.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10906907      PMCID: PMC1230847     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  634 in total

1.  Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

Authors:  C P van Schayck; S J Graafsma; M B Visch; E Dompeling; C van Weel; C L van Herwaarden
Journal:  J Allergy Clin Immunol       Date:  1990-11       Impact factor: 10.793

2.  Canadian Thoracic Society guidelines for occupational asthma.

Authors:  S M Tarlo; L P Boulet; A Cartier; D Cockcroft; J Côtè; F E Hargreave; L Holness; G Liss; J L Malo; M Chan-Yeung
Journal:  Can Respir J       Date:  1998 Jul-Aug       Impact factor: 2.409

Review 3.  New insights into the pathogenesis and management of steroid-resistant asthma.

Authors:  J D Spahn; D Y Leung; S J Szefler
Journal:  J Asthma       Date:  1997       Impact factor: 2.515

4.  Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.

Authors:  L Thorsson; K Dahlström; S Edsbäcker; A Källén; J Paulson; J E Wirén
Journal:  Br J Clin Pharmacol       Date:  1997-02       Impact factor: 4.335

5.  Allergen avoidance in house dust mite sensitive adult asthma.

Authors:  M J Walshaw; C C Evans
Journal:  Q J Med       Date:  1986-02

6.  France seeks to curb health costs by fining doctors.

Authors:  J Dixon
Journal:  BMJ       Date:  1997-10-11

7.  A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma.

Authors:  C T Furukawa; G G Shapiro; C W Bierman; M J Kraemer; D J Ward; W E Pierson
Journal:  Pediatrics       Date:  1984-10       Impact factor: 7.124

8.  Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma.

Authors:  R M Nowak; M I Pensler; D D Sarkar; J A Anderson; P A Kvale; A E Ortiz; M C Tomlanovich
Journal:  Ann Emerg Med       Date:  1982-02       Impact factor: 5.721

9.  Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma.

Authors:  J Crane; N Pearce; C Burgess; K Woodman; B Robson; R Beasley
Journal:  Int J Epidemiol       Date:  1992-08       Impact factor: 7.196

10.  Cyclosporin for steroid-dependent asthma.

Authors:  A Szczeklik; E Nizankowska; R Dworski; B Domagala; G Pinis
Journal:  Allergy       Date:  1991-05       Impact factor: 13.146

View more
  129 in total

1.  Guidelines do matter.

Authors:  N Anthonisen
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 2.  The use of sputum cell counts to evaluate asthma medications.

Authors:  K Parameswaran; F E Hargreave
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

3.  Asthma programme in Finland: a community problem needs community solutions.

Authors:  T Haahtela; T Klaukka; K Koskela; M Erhola; L A Laitinen
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

4.  Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma.

Authors:  A L Kozyrskyj; C A Mustard; M S Cheang; F E Simons
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

5.  Inhaled corticosteroids and COPD.

Authors:  D Farquhar
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 6.  Occupational asthma: an approach to diagnosis and management.

Authors:  Susan M Tarlo; Gary M Liss
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

7.  Drug marketing: unsafe at any dose?

Authors: 
Journal:  CMAJ       Date:  2002-10-29       Impact factor: 8.262

8.  Should combination therapy with inhaled corticosteroids and long-acting beta2-agonists be prescribed as initial maintenance treatment for asthma?

Authors:  Catherine Lemière; Allan Becker; Louis-Philippe Boulet; Dennis Bowie; André Cartier; Donald Cockroft; Robert Cowie; Pierre Ernst; Mark Fitzgerald; Malcolm Sears; Sheldon Spier
Journal:  CMAJ       Date:  2002-10-29       Impact factor: 8.262

Review 9.  Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 10.  Salmeterol (Serevent) asthma trial halted early.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.